Speaker illustration

Doctor Christopher Blaum

The University Medical Center Hamburg-Eppendorf, Hamburg (Germany)

Member of:

European Society of Cardiology

Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipid-Lowering Agents

Session: Highlights from the Young on cutting edge therapy for lowering lipids


Risk scores for risk stratification in chronic coronary syndrome and their improvement by Gensini and SYNTAX scores

Event: ESC Congress 2021 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Coronary Artery Disease (Chronic)/Chronic Coronary Syndromes ePosters


The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort

Event: ESC Congress 2020

Topic: Drug therapy

Session: Risk Factors and Prevention ePosters


The impact of modifiable life style risk factors on inflammation in patients with coronary artery disease: modelling a target population for anti-inflammatory treatment

Event: ESC Congress 2019

Topic: Lifestyle Modification

Session: CAD - Lifestyle modification and non-pharmacological treatment


ESC 365 is supported by

logo Novo Nordisk